+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Generics North America (NAFTA) Industry Guide 2014-2023

  • ID: 5004334
  • Report
  • February 2020
  • Region: North America
  • 70 pages
  • MarketLine
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Apotex, Inc.
  • Mylan N.V.
  • Pfizer Inc.
  • MORE
Generics North America (NAFTA) Industry Guide 2014-2023

Summary

The NAFTA Generics industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2014-18, and forecast to 2023). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Essential resource for top-line data and analysis covering the NAFTA generics market. Includes market size data, textual and graphical analysis of market growth trends and leading companies.

Key Highlights
  • The North American Free Trade Agreement (NAFTA) is a trade agreement between the countries in North America: the US, Canada and Mexico. The generics industry within the NAFTA countries had a total market value of $116,377.6 million in 2018.The Mexico was the fastest growing country, with a CAGR of 12.5% over the 2014-18 period.
  • Within the generics industry, the US is the leading country among the NAFTA bloc, with market revenues of $104,841.0 million in 2018. This was followed by Mexico and Canada, with a value of $6,337.2 and $5,199.4 million, respectively.
  • The US is expected to lead the generics industry in the NAFTA bloc, with a value of $124,641.3 million in 2023, followed by Mexico and Canada with expected values of $8,519.8 and $6,002.7 million, respectively.
Scope
  • Save time carrying out entry-level research by identifying the size, growth, and leading players in the NAFTA generics market
  • Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the NAFTA generics market
  • Leading company profiles reveal details of key generics market players’ NAFTA operations and financial performance
  • Add weight to presentations and pitches by understanding the future growth prospects of the NAFTA generics market with five year forecasts by both value and volume
  • Compares data from the US, Canada and Mexico, alongside individual chapters on each country
Reasons to buy
  • What was the size of the NAFTA generics market by value in 2018?
  • What will be the size of the NAFTA generics market in 2023?
  • What factors are affecting the strength of competition in the NAFTA generics market?
  • How has the market performed over the last five years?
  • How large is the NAFTA generics market in relation to its regional counterparts?
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Apotex, Inc.
  • Mylan N.V.
  • Pfizer Inc.
  • MORE
1 Introduction
1.1. What is this report about?
1.2. Who is the target reader?
1.3. How to use this report
1.4. Definitions

2 NAFTA Generics
2.1. Industry Outlook

3 Generics in Canada
3.1. Market Overview
3.2. Market Data
3.3. Market Segmentation
3.4. Market outlook
3.5. Five forces analysis
3.6. Macroeconomic Indicators
3.7. Country data

4 Generics in Mexico
4.1. Market Overview
4.2. Market Data
4.3. Market Segmentation
4.4. Market outlook
4.5. Five forces analysis
4.6. Macroeconomic Indicators
4.7. Country data

5 Generics in the United States
5.1. Market Overview
5.2. Market Data
5.3. Market Segmentation
5.4. Market outlook
5.5. Five forces analysis
5.6. Macroeconomic Indicators
5.7. Country data

6 Company Profiles
6.1. Pfizer Inc.
6.2. Teva Pharmaceutical Industries Limited
6.3. Apotex, Inc.
6.4. Mylan N.V.

Appendix

List of Tables
Table 1: NAFTA countries Generics industry, revenue ($m), 2014-23
Table 2: NAFTA countries Generics industry, revenue ($m), 2014-18
Table 3: NAFTA countries Generics industry forecast, revenue ($m), 2018-23
Table 4: Canada generics market value: $ million, 2014-18
Table 5: Canada generics market volume: % of total pharma, 2014-18
Table 6: Canada generics market geography segmentation: $ million, 2018
Table 7: Canada generics market value forecast: $ million, 2018-23
Table 8: Canada generics market volume forecast: % of total pharma, 2018-23
Table 9: Canada size of population (million), 2014-18
Table 10: Canada gdp (constant 2005 prices, $ billion), 2014-18
Table 11: Canada gdp (current prices, $ billion), 2014-18
Table 12: Canada inflation, 2014-18
Table 13: Canada consumer price index (absolute), 2014-18
Table 14: Canada exchange rate, 2014-18
Table 15: Mexico generics market value: $ million, 2014-18
Table 16: Mexico generics market volume: % of total pharma, 2014-18
Table 17: Mexico generics market geography segmentation: $ million, 2018
Table 18: Mexico generics market value forecast: $ million, 2018-23
Table 19: Mexico generics market volume forecast: % of total pharma, 2018-23
Table 20: Mexico size of population (million), 2014-18
Table 21: Mexico gdp (constant 2005 prices, $ billion), 2014-18
Table 22: Mexico gdp (current prices, $ billion), 2014-18
Table 23: Mexico inflation, 2014-18
Table 24: Mexico consumer price index (absolute), 2014-18
Table 25: Mexico exchange rate, 2014-18
Table 26: United States generics market value: $ million, 2014-18
Table 27: United States generics market volume: % of total pharma, 2014-18
Table 28: United States generics market geography segmentation: $ million, 2018
Table 29: United States generics market value forecast: $ million, 2018-23
Table 30: United States generics market volume forecast: % of total pharma, 2018-23
Table 31: United States size of population (million), 2014-18
Table 32: United States gdp (constant 2005 prices, $ billion), 2014-18
Table 33: United States gdp (current prices, $ billion), 2014-18
Table 34: United States inflation, 2014-18
Table 35: United States consumer price index (absolute), 2014-18
Table 36: United States exchange rate, 2014-18
Table 37: Pfizer Inc.: key facts
Table 38: Pfizer Inc.: Annual Financial Ratios
Table 39: Pfizer Inc.: Key Employees
Table 40: Pfizer Inc.: Key Employees Continued
Table 41: Teva Pharmaceutical Industries Limited: key facts
Table 42: Teva Pharmaceutical Industries Limited: Annual Financial Ratios
Table 43: Teva Pharmaceutical Industries Limited: Key Employees
Table 44: Apotex, Inc.: key facts
Table 45: Apotex, Inc.: Key Employees
Table 46: Mylan N.V.: key facts
Table 47: Mylan N.V.: Annual Financial Ratios
Table 48: Mylan N.V.: Key Employees

List of Figures
Figure 1: NAFTA countries Generics industry, revenue ($m), 2014-23
Figure 2: NAFTA countries Generics industry, revenue ($m), 2014-18
Figure 3: NAFTA countries Generics industry forecast, revenue ($m), 2018-23
Figure 4: Canada generics market value: $ million, 2014-18
Figure 5: Canada generics market volume: % of total pharma, 2014-18
Figure 6: Canada generics market geography segmentation: % share, by value, 2018
Figure 7: Canada generics market value forecast: $ million, 2018-23
Figure 8: Canada generics market volume forecast: % of total pharma, 2018-23
Figure 9: Forces driving competition in the generics market in Canada, 2018
Figure 10: Drivers of buyer power in the generics market in Canada, 2018
Figure 11: Drivers of supplier power in the generics market in Canada, 2018
Figure 12: Factors influencing the likelihood of new entrants in the generics market in Canada, 2018
Figure 13: Factors influencing the threat of substitutes in the generics market in Canada, 2018
Figure 14: Drivers of degree of rivalry in the generics market in Canada, 2018
Figure 15: Mexico generics market value: $ million, 2014-18
Figure 16: Mexico generics market volume: % of total pharma, 2014-18
Figure 17: Mexico generics market geography segmentation: % share, by value, 2018
Figure 18: Mexico generics market value forecast: $ million, 2018-23
Figure 19: Mexico generics market volume forecast: % of total pharma, 2018-23
Figure 20: Forces driving competition in the generics market in Mexico, 2018
Figure 21: Drivers of buyer power in the generics market in Mexico, 2018
Figure 22: Drivers of supplier power in the generics market in Mexico, 2018
Figure 23: Factors influencing the likelihood of new entrants in the generics market in Mexico, 2018
Figure 24: Factors influencing the threat of substitutes in the generics market in Mexico, 2018
Figure 25: Drivers of degree of rivalry in the generics market in Mexico, 2018
Figure 26: United States generics market value: $ million, 2014-18
Figure 27: United States generics market volume: % of total pharma, 2014-18
Figure 28: United States generics market geography segmentation: % share, by value, 2018
Figure 29: United States generics market value forecast: $ million, 2018-23
Figure 30: United States generics market volume forecast: % of total pharma, 2018-23
Figure 31: Forces driving competition in the generics market in the United States, 2018
Figure 32: Drivers of buyer power in the generics market in the United States, 2018
Figure 33: Drivers of supplier power in the generics market in the United States, 2018
Figure 34: Factors influencing the likelihood of new entrants in the generics market in the United States, 2018
Figure 35: Factors influencing the threat of substitutes in the generics market in the United States, 2018
Figure 36: Drivers of degree of rivalry in the generics market in the United States, 2018
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Limited
  • Apotex, Inc.
  • Mylan N.V.
Note: Product cover images may vary from those shown
Adroll
adroll